BioVaxys Technology (FRA:5LB0) Inventory Turnover: 0.00 (As of Jul. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BioVaxys Technology Inventory Turnover?

BioVaxys Technology FRA:5LB0 Inventory Turnover is 0.00 as of Jul. 2025.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. BioVaxys Technology's Cost of Goods Sold for the three months ended in Jul. 2025 was €0.00 Mil. BioVaxys Technology's Average Total Inventories for the quarter that ended in Jul. 2025 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioVaxys Technology  (FRA:5LB0) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioVaxys Technology's Days Inventory for the three months ended in Jul. 2025 is calculated as:

Days Inventory =Average Total Inventories (Q: Jul. 2025 )/Cost of Goods Sold (Q: Jul. 2025 )*Days in Period
=0/0*365 / 4
=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioVaxys Technology's Inventory to Revenue for the quarter that ended in Jul. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jul. 2025 ) / Revenue (Q: Jul. 2025 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

BioVaxys Technology Inventory Turnover Related Terms

BioVaxys Technology Inventory Turnover Historical Data

* Premium members only.

The historical data trend for BioVaxys Technology's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVaxys Technology Inventory Turnover Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Inventory Turnover
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

BioVaxys Technology Quarterly Data
Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioVaxys Technology Inventory Turnover Calculation

BioVaxys Technology's Inventory Turnover for the fiscal year that ended in Oct. 2024 is calculated as

Inventory Turnover (A: Oct. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Oct. 2024 ) / ((Total Inventories (A: Oct. 2023 ) + Total Inventories (A: Oct. 2024 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

BioVaxys Technology's Inventory Turnover for the quarter that ended in Jul. 2025 is calculated as

Inventory Turnover (Q: Jul. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jul. 2025 ) / ((Total Inventories (Q: Apr. 2025 ) + Total Inventories (Q: Jul. 2025 )) / count )
=0 / ((0 + 0) / 1 )
=0 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.00 mean?
BioVaxys Technology (FRA:5LB0) has a Inventory Turnover of 0.00 as of Jul. 2025. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BioVaxys Technology and its competitors.
Is BioVaxys Technology's Inventory Turnover too high?
BioVaxys Technology's current Inventory Turnover is 0.00.
How does BioVaxys Technology's Inventory Turnover compare to BPTH and AZTR?
BioVaxys Technology's Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BioVaxys Technology and its competitors. BioVaxys Technology's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (FRA:5LB0) has a current Inventory Turnover of 0.00. The current Inventory Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For BioVaxys Technology (FRA:5LB0), the current Inventory Turnover is 0.00 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVaxys Technology Business Description

Other Exchanges BVAXF:USABIOV:Canada
Address 595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.